Robust pipeline is expected to bring significant savings in the autoimmune category
The launch of Amgen’s Amjevita — the first of many Humira biosimilars expected to launch in 2023 and 2024 — presents an opportunity to meaningfully reduce drug costs. Over the next two years, we expect plan sponsors to benefit from significant savings in the autoimmune categories where biosimilar competition exists.
What payors need to know
We’ve seen that these products can create competition that drives significant savings. Our primer, Biosimilars in the Autoimmune Category – Opportunities and Considerations, highlights the complex factors that affect formulary decisions around biosimilars.
It explores upcoming entrants in the autoimmune category and how our approach is aligned to our lowest net cost strategy, providing our clients with maximum savings, while providing members coverage of clinically safe, effective medications and ensuring continuity of care.
Reviewing new-to-market biosimilars
Josh Fredell explains our new-to-market evaluation
A thoughtful approach to assessing new products is key to informing our lowest net cost strategy. New biosimilars undergo our proven new-to-market evaluation. With each entrant, we review cost and clinical considerations, including formulation, delivery mechanism, sufficient supply, and member experience.
We'll continue to use this framework to evaluate additional products as they come to market. Our strategy will evolve with the expected launch of up to 10 Humira biosimilars in 2023 followed by anticipated biosimilars for Stelara in 2024.
With each biosimilar launch, we’re focused on making the best decision – one that maximizes savings for payors and minimizes disruption for members.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health.
©2023 CVS Health. All rights reserved. 013023